Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model

Pawel A Mroz, Michael R. Hamblin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

2 Citations (Scopus)

Abstract

Epigenetic mechanisms, which involve DNA methylation and histone modifications, result in the heritable silencing of genes without a change in their coding sequence. However, these changes must be actively maintained after each cell division rendering them a promising target for pharmacologic inhibition. DNA methyltransferase inhibitors like 5-aza-deoxycytidine (5-aza-dC) induce and/or up-regulate the expression of MAGE-type antigens in human and mice cancer cells. Photodynamic therapy (PDT) has been shown to be an effective locally ablative anti-cancer treatment that has the additional advantage of stimulating tumor-directed immune response. We studied the effects of a new therapy that combined the demethylating agent 5-aza-dC with PDT in the breast cancer model 4T1 syngenic to immunocompetent BALB/c mice. PDT was used as a locally ablating tumor treatment that is capable of eliciting strong and tumor directed immune response while 5-aza-dC pretreatment was used promote de novo induction of the expression of P1A.protein. This is the mouse homolog of human MAGE family antigens and is reported to function as a tumor rejection antigen in certain mouse tumors. This strategy led to an increase in PDT-mediated immune response and better treatment outcome. These results strongly suggest that the MAGE family antigens are important target for PDT mediated immune response but that their expression can be silenced by epigenetic mechanisms. Therefore the possibility that PDT can be combined with epigenetic strategies to elicit anti-tumor immunity in MAGE-positive tumor models is highly clinically significant and should be studied in detail.

Original languageEnglish (US)
Title of host publication12th World Congress of the International Photodynamic Association - Photodynamic Therapy
Subtitle of host publicationBack to the Future
Volume7380
DOIs
StatePublished - Dec 1 2009
Externally publishedYes
Event12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future - Seattle, WA, United States
Duration: Jun 11 2009Jun 15 2009

Other

Other12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future
CountryUnited States
CitySeattle, WA
Period6/11/096/15/09

Fingerprint

Photodynamic therapy
Photochemotherapy
mice
Tumors
therapy
DNA
tumors
deoxyribonucleic acid
antigens
Antigens
Deoxycytidine
Neoplasms
Epigenomics
cancer
Cells
Histone Code
cell division
methylation
Oncology
immunity

Keywords

  • 5-aza-deoxycytidine
  • epigenetics
  • MAGE
  • photodynamic therapy
  • tumor antigens

Cite this

Mroz, P. A., & Hamblin, M. R. (2009). Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model. In 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future (Vol. 7380). [73800H] https://doi.org/10.1117/12.823005

Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model. / Mroz, Pawel A; Hamblin, Michael R.

12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future. Vol. 7380 2009. 73800H.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Mroz, PA & Hamblin, MR 2009, Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model. in 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future. vol. 7380, 73800H, 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future, Seattle, WA, United States, 6/11/09. https://doi.org/10.1117/12.823005
Mroz PA, Hamblin MR. Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model. In 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future. Vol. 7380. 2009. 73800H https://doi.org/10.1117/12.823005
Mroz, Pawel A ; Hamblin, Michael R. / Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model. 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future. Vol. 7380 2009.
@inproceedings{70af1274f4884db697e5e1621658e835,
title = "Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model",
abstract = "Epigenetic mechanisms, which involve DNA methylation and histone modifications, result in the heritable silencing of genes without a change in their coding sequence. However, these changes must be actively maintained after each cell division rendering them a promising target for pharmacologic inhibition. DNA methyltransferase inhibitors like 5-aza-deoxycytidine (5-aza-dC) induce and/or up-regulate the expression of MAGE-type antigens in human and mice cancer cells. Photodynamic therapy (PDT) has been shown to be an effective locally ablative anti-cancer treatment that has the additional advantage of stimulating tumor-directed immune response. We studied the effects of a new therapy that combined the demethylating agent 5-aza-dC with PDT in the breast cancer model 4T1 syngenic to immunocompetent BALB/c mice. PDT was used as a locally ablating tumor treatment that is capable of eliciting strong and tumor directed immune response while 5-aza-dC pretreatment was used promote de novo induction of the expression of P1A.protein. This is the mouse homolog of human MAGE family antigens and is reported to function as a tumor rejection antigen in certain mouse tumors. This strategy led to an increase in PDT-mediated immune response and better treatment outcome. These results strongly suggest that the MAGE family antigens are important target for PDT mediated immune response but that their expression can be silenced by epigenetic mechanisms. Therefore the possibility that PDT can be combined with epigenetic strategies to elicit anti-tumor immunity in MAGE-positive tumor models is highly clinically significant and should be studied in detail.",
keywords = "5-aza-deoxycytidine, epigenetics, MAGE, photodynamic therapy, tumor antigens",
author = "Mroz, {Pawel A} and Hamblin, {Michael R.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1117/12.823005",
language = "English (US)",
isbn = "9780819476609",
volume = "7380",
booktitle = "12th World Congress of the International Photodynamic Association - Photodynamic Therapy",

}

TY - GEN

T1 - Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model

AU - Mroz, Pawel A

AU - Hamblin, Michael R.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Epigenetic mechanisms, which involve DNA methylation and histone modifications, result in the heritable silencing of genes without a change in their coding sequence. However, these changes must be actively maintained after each cell division rendering them a promising target for pharmacologic inhibition. DNA methyltransferase inhibitors like 5-aza-deoxycytidine (5-aza-dC) induce and/or up-regulate the expression of MAGE-type antigens in human and mice cancer cells. Photodynamic therapy (PDT) has been shown to be an effective locally ablative anti-cancer treatment that has the additional advantage of stimulating tumor-directed immune response. We studied the effects of a new therapy that combined the demethylating agent 5-aza-dC with PDT in the breast cancer model 4T1 syngenic to immunocompetent BALB/c mice. PDT was used as a locally ablating tumor treatment that is capable of eliciting strong and tumor directed immune response while 5-aza-dC pretreatment was used promote de novo induction of the expression of P1A.protein. This is the mouse homolog of human MAGE family antigens and is reported to function as a tumor rejection antigen in certain mouse tumors. This strategy led to an increase in PDT-mediated immune response and better treatment outcome. These results strongly suggest that the MAGE family antigens are important target for PDT mediated immune response but that their expression can be silenced by epigenetic mechanisms. Therefore the possibility that PDT can be combined with epigenetic strategies to elicit anti-tumor immunity in MAGE-positive tumor models is highly clinically significant and should be studied in detail.

AB - Epigenetic mechanisms, which involve DNA methylation and histone modifications, result in the heritable silencing of genes without a change in their coding sequence. However, these changes must be actively maintained after each cell division rendering them a promising target for pharmacologic inhibition. DNA methyltransferase inhibitors like 5-aza-deoxycytidine (5-aza-dC) induce and/or up-regulate the expression of MAGE-type antigens in human and mice cancer cells. Photodynamic therapy (PDT) has been shown to be an effective locally ablative anti-cancer treatment that has the additional advantage of stimulating tumor-directed immune response. We studied the effects of a new therapy that combined the demethylating agent 5-aza-dC with PDT in the breast cancer model 4T1 syngenic to immunocompetent BALB/c mice. PDT was used as a locally ablating tumor treatment that is capable of eliciting strong and tumor directed immune response while 5-aza-dC pretreatment was used promote de novo induction of the expression of P1A.protein. This is the mouse homolog of human MAGE family antigens and is reported to function as a tumor rejection antigen in certain mouse tumors. This strategy led to an increase in PDT-mediated immune response and better treatment outcome. These results strongly suggest that the MAGE family antigens are important target for PDT mediated immune response but that their expression can be silenced by epigenetic mechanisms. Therefore the possibility that PDT can be combined with epigenetic strategies to elicit anti-tumor immunity in MAGE-positive tumor models is highly clinically significant and should be studied in detail.

KW - 5-aza-deoxycytidine

KW - epigenetics

KW - MAGE

KW - photodynamic therapy

KW - tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=79959715423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959715423&partnerID=8YFLogxK

U2 - 10.1117/12.823005

DO - 10.1117/12.823005

M3 - Conference contribution

SN - 9780819476609

VL - 7380

BT - 12th World Congress of the International Photodynamic Association - Photodynamic Therapy

ER -